Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-UK vaccine roll-out to be slower than hoped, deliveries to pick up from May

Thu, 18th Mar 2021 07:17

* UK says global lumpy supply chain causing issues

* UK vaccine roll-out will be slower than hoped

* UK says vaccine deliveries to rise from May

* UK scolds EU over vaccine ban threat
(Adds detail, reaction from companies)

By Guy Faulconbridge and Kate Holton

LONDON, March 18 (Reuters) - Britain said on Thursday that
global supply bumps meant its vaccine roll-out would be slower
than hoped in coming weeks but it expected deliveries to
increase again in May, June and July.

British health officials warned on Wednesday that the
world's fastest big economy roll-out of the vaccine would face a
significant reduction in supplies from March 29.

Pfizer Inc and AstraZeneca Plc said their
delivery schedules had not been impacted, and Housing Secretary
Robert Jenrick refused to be drawn on whether the issue was due
to a problem with supply from India.

"We have less supply than we might have hoped for the coming
weeks but we expect it to increase again later," Jenrick told
the BBC.

"The vaccine roll-out will be slightly slower than we might
have hoped but not slower than the target," he said. "We have
every reason to believe that supply will increase in the months
of May, June and July."

Britain is on track to have given a first shot to half of
all adults in the next few days, making it one of the fastest
countries to roll out a vaccine.

So far 25.27 million people in the United Kingdom have had a
vaccine, around 48% of adults, and Jenrick said Britain remained
on track to have vaccinated priority groups by April 15 and all
adults by the end of July.

"We always said right from the beginning that a new
manufacturing process would have its lumps and bumps and that
has been the case in the past and I'm sure it will be in the
future," Jenrick told Sky.

"We're sourcing vaccines from all over the world and we are
experiencing occasionally some issues and that's led to this,
this issue with some supply in the coming weeks," he said.

Asked if the issue was supply from India, he declined to
discuss specific contracts.

SUPPLY BUMP

Britain is rolling out vaccines made by Pfizer and
AstraZeneca, with 10 million doses of the 100 million ordered
from AstraZeneca coming from the Serum Institute in India.

AstraZeneca said its domestic supply chain, which produces
most of its supply for Britain, was unaffected.

"Our UK domestic supply chain is not experiencing any
disruption and there is no impact on our delivery schedule,"
said a spokesman for the firm, which makes the vaccine developed
by the University of Oxford.

The announcement of a supply shortfall coincided with a
resurgence in tensions with the European Union, which is
frustrated by a lack of exports of AstraZeneca's vaccine from
Britain.

The EU threatened on Wednesday to ban exports of COVID-19
vaccines to Britain to safeguard scarce doses for its own
citizens, and Jenrick said the threat from European Commission
head Ursula von der Leyen was disappointing.

Pfizer, which supplies Britain with shots from Europe, said
first quarter deliveries to the UK remained on track and overall
supply for the second quarter remained unchanged. Jenrick said
he hoped no barriers to the importation of vaccines would be
erected by the bloc.

"I was surprised and disappointed by those comments but the
prime minister had spoken earlier in the year to Ursula von der
Leyen and she gave a very clear commitment, which was that the
EU would not engage in this sort of activity, that contractual
responsibilities would be honoured," Jenrick said.

"And that's exactly what we intend to do and I hope and
expect the EU to stick to their side of the bargain."
(Reporting by Guy Faulconbridge, Kate Holton and Alistair
Smout; editing by Sarah Young and Giles Elgood)

More News
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
21 May 2024 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
21 May 2024 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
21 May 2024 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:56

AstraZeneca to build $1.5-bln cancer drug plant in Singapore

Plans to build ADCs manufacturing facility in Singapore

*

Read more
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more
20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).

Read more
17 May 2024 22:25

Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial

May 17 (Reuters) - AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.

Read more
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.